Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Off-label prescription of hydroxycarbamide (hydroxyurea, HU) for severe anemia: preliminary results from European non-interventional, multicentric, prospective escort-HU study
source: American Society of Hematology
year: 2017
authors: Mariane De Montalembert, Gylna Loko, Jerome Clouzeau, Valentine Brousse, Frederic Galacteros, Corinne Charneau, Marie Belloy, Malika Benkerrou
summary/abstract:HU is licensed in Europe in the prevention of recurrent painful vaso-occlusive crises (VOC) including acute chest syndromes in adults, adolescents and children older than 2 years with sickle-cell disease (SCD). However, based on US and European expert panel recommendations (Yawn 2014, Habibi 2015) and results from placebo-controlled clinical trials, HU could be useful in SCD patients with severe anemia without VOC since it has been demonstrated to increase total Hb level (Wang 2011) and to decrease the need for blood transfusion. We hereby present preliminary results on effectiveness and safety data related to the prescription of HU for anemia from ESCORT-HU (European Sickle Cell Disease COhoRT – HydroxyUrea), a multicentric, prospective, non-interventional European study designed to collect long-term safety data on HU in SCD population. Between January 2009 and June 2017, 1841 patients were enrolled from 63 centers in France, Germany, Greece and Italy, amongst which 126 patients (6.8%) were started on HU for anemia from 34 centers. Of these 126, 96 were HU-naive. These HU-naive patients treated for anemia (‘anemic’ subpopulation) were selected for analysis to evaluate effectiveness and safety of HU in this indication and compared with data in HU-naive patients treated for other SCD indications. Demographic data and Hb genotypes are displayed in Table 1. The mean age, distribution of gender, Hb genotype and the mean HU dose at initiation were comparable in the ‘anemic’ subpopulation and the ‘non-anemic’ HU-naive cohort. Not surprisingly, mean Hb level at initiation was markedly lower in the ‘anemic’ subpopulation (7.07 ± 0.88 g/dl) than in the ‘non-anemic’ HU-naive cohort (8.71 ± 1.51 g/dl), with a lower proportion of patients with history of VOC and SCD-related hospitalization prior to HU initiation. The mean HU dose after 6 months was comparable in both groups (15.6 ± 3.83 mg/kg/day and 15.4 ± 4.11 mg/kg/day, respectively).
organization: Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Laboratory of Excellence, GR-Ex, Paris, France; Martinique University Hospital, Le Lamentin, Martinique; Franck-Joly Hospital, Saint-Laurent du Maroni, Guyana; Henri Mondor Hospital - APHP, Creteil, France; Basse-Terre Hospital, Basse-Terre, Guadeloupe; Robert-Ballanger Hospital, Aulnay-sous-Bois, France; Robert Debré Hospital - APHP, Paris, Franceread more
+myBinderRelated Content
-
Updated Mechanisms Underlying Sickle Cell Disease-Associated PainSickle cell disease (SCD) is one of the ...
-
Successful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
-
Toronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
-
A Validated Measure of Adherence to Antibiotic Prophylaxis in Children With Sickle Cell DiseaseAntibiotic prophylaxis is a mainstay in ...
-
Kids with sickle cell disease aren’t receiving key vaccines, Michigan study findsA significant proportion of children w...
-
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.